2010 Fiscal Year Final Research Report
Pathophysiological role of chymase in complications of metabolic syndrome
| Project/Area Number |
20590265
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
TAKAI Shinji Osaka Medical College, 医学部, 准教授 (80288703)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
JIN Denan 大阪医科大学, 医学部, 講師 (90319533)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Keywords | キマーゼ / メタボリックシンドローム / 糖尿病 / 高脂血症 / 臓器障害 / 脂肪肝 / 線維化 / 大動脈瘤 |
|---|
| Research Abstract |
Chymase converts precursors of angiotensin (Ang) II, Transforming growth factor (TGF)-β and matrix metalloproteinase (MMP)-9 to their active forms. In a diabetic animal model, chymase induced pancreatic disorganization by augmentation of chymase-forming Ang II. In an animal model with abdominal aneurysmal aorta (AAA), the inhibition of MMP-9 activation by chymase inhibitor resulted in attenuation of the AAA progression. Steatosis and fiblosis in liver were strongly prevented by chymase inhibition in an animal model with nonalcoholic steatohepatitis. These results demonstrated that chymase plays a crucial role in complications of metabolic syndrome.
|
